Orforglipron received FDA approval under the brand name Foundayo
Appetite suppression through dopamine modulation Central appetite control: Tesofensine acts on hypothalamus Affects arcuate nucleus (appetite center) Different pathway from GLP-1 receptors Direct neurotransmitter modulation Rapid onset (hours not days) Dopamine's role in eating: Mediates food reward (hedonic eating) High-dopamine = reduced food seeking Decreases obsessive food thoughts Reduces binge eating tendencies Similar to ADHD medication effects Subjective appetite changes reported: Reduced hunger (moderate, not as strong as semaglutide ) Less food preoccupation Earlier satiety (smaller portions satisfying) Reduced cravings especially for high-calorie foods More mental focus on non-food activities Appetite suppression comparison: Why dopamine approach different: Addresses psychological/behavioral eating Reduces food as reward behavior Helps with emotional eating Less GI side effects than GLP-1s But creates stimulant-like dependency risk Clinical trial results and efficacy Evidence from human studies
This is well documented
Retatrutide works partly by suppressing appetite and slowing gastric emptying, but if caloric intake remains high particularly from ultra-processed foods, sugary drinks, or alcohol weight loss will be limited
Retatrutide and the Grey Market: Buyer Beware This should go without saying, but the internet can be both an incredible resource and an extremely dangerous place for health and wellness information
The drug, retatrutide, is designed to lower blood sugar, reduce appetite and increase energy expenditure
